Mackenzie Financial Corp Intra Cellular Therapies, Inc. Transaction History

Mackenzie Financial Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$64.76 - $79.84 $155,877 - $192,174	-2,407 Reduced 32.86%	4,919 $336,000
Q1 2024 May 10, 2024	BUY	$64.37 - $75.65 $211,712 - $248,812	3,289 Added 81.47%	7,326 $506,000
Q4 2023 Jan 30, 2024	BUY	$46.37 - $73.65 $187,195 - $297,325	4,037 New	4,037 $289,000
Q2 2023 Aug 03, 2023	BUY	$54.67 - $66.44 $106,387 - $129,292	1,946 Added 34.49%	7,589 $480,000
Q4 2022 Feb 14, 2023	SELL	$44.07 - $54.45 $13,132 - $16,226	-298 Reduced 5.02%	5,643 $298,000
Q3 2022 Oct 07, 2022	SELL	$42.7 - $59.99 $2.18 Million - $3.06 Million	-50,989 Reduced 89.56%	5,941 $276,000
Q2 2022 Aug 10, 2022	BUY	$43.0 - $65.64 $2.25 Million - $3.44 Million	52,389 Added 1153.69%	56,930 $3.25 Million
Q1 2022 May 13, 2022	BUY	$38.74 - $62.09 $27,118 - $43,463	700 Added 18.22%	4,541 $278,000
Q4 2021 Feb 14, 2022	BUY	$35.2 - $53.42 $135,203 - $205,186	3,841 New	3,841 $201,000

379

84.7M

319K

143K

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $7.87B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Mackenzie Financial Corp with notifications on news.